Literature DB >> 15531733

Alternatives to nitric oxide.

Stuart M Lowson1.   

Abstract

Inhaled nitric oxide (INO) is a selective pulmonary vasodilator that has the ability to produce vasodilation in the pulmonary vascular bed without causing it in the systemic circulation. This property of INO has made it a useful therapy in the management of both adult and paediatric patients with a variety of conditions associated with pulmonary hypertension (PH), with or without hypoxia. Toxicity, cost and negative-outcome studies have prompted a search for alternative agents. These include inhaled prostacyclin and alternative prostaglandin preparations such as inhaled iloprost, treprostinol and beraprost. The phospodiesterase inhibitors show real potential in the management of both acute and chronic forms of PH, and antagonists of endogenous pulmonary vasoconstrictors, such as endothelin and thromboxane, are being evaluated for the long-term treatment of conditions such as primary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531733     DOI: 10.1093/bmb/ldh028

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  5 in total

1.  Inhaled Pulmonary Vasodilators in Cardiac Surgery Patients: Correct Answer Is "NO".

Authors:  Fumito Ichinose; Warren M Zapol
Journal:  Anesth Analg       Date:  2017-08       Impact factor: 5.108

Review 2.  On the right side of the heart: Medical and mechanical support of the failing right ventricle.

Authors:  Ignacio de Asua; Alex Rosenberg
Journal:  J Intensive Care Soc       Date:  2017-01-03

3.  Nitric Oxide-Dependent Feedback Loop Regulates Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Cooperativity and Endothelial Function in Small Pulmonary Arteries.

Authors:  Corina Marziano; Kwangseok Hong; Eric L Cope; Michael I Kotlikoff; Brant E Isakson; Swapnil K Sonkusare
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

Review 4.  Delivery of Antioxidant and Anti-inflammatory Agents for Tissue Engineered Vascular Grafts.

Authors:  Kenyatta S Washington; Chris A Bashur
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810

Review 5.  Treatment of pediatric pulmonary hypertension.

Authors:  Amy Hawkins; Robert Tulloh
Journal:  Vasc Health Risk Manag       Date:  2009-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.